Patents by Inventor Joseph B. Santella

Joseph B. Santella has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HETEROARYL SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE MODULATORS
    Publication number: 20150284382
    Abstract: Compounds having the following formula (I) or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein R2 is a monocyclic heteroaryl group, and R1, R3, R4, R5 and R6 are as defined herein, are useful as kinase modulators, including IRAK-4 inhibition.
    Type: Application
    Filed: November 7, 2013
    Publication date: October 8, 2015
    Inventors: Rajeev S. Bhide, John V. Duncia, John Hynes, Satheesh K. Nair, William J. Pitts, Sreekantha R. Kumar, Daniel S. Gardner, Natesan Murugesan, Venkatram Reddy Paidi, Joseph B. Santella, Ramesh Sistla, Hong Wu
  • BICYCLIC HETEROCYCLE SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE MODULATORS
    Publication number: 20150274696
    Abstract: Compounds having the following formula (I) or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein R2 is a bicyclic heterocycle, and R1, R3, R4, R5 and R6 are as defined herein, that are useful as kinase modulators, including IRAK-4 modulation.
    Type: Application
    Filed: November 7, 2013
    Publication date: October 1, 2015
    Inventors: Rajeev S. Bhide, John V. Duncia, John Hynes, Satheesh K. Nair, William J. Pitts, Sreekantha R. Kumar, Daniel S. Gardner, Natesan Murugesan, Venkatram Reddy Paidi, Joseph B. Santella, Ramesh Sistla, Hong Wu
  • HETEROARYL SUBSTITUTED NICOTINAMIDE COMPOUNDS
    Publication number: 20150191464
    Abstract: Disclosed are compounds of Formula (I) or salts thereof, wherein: HET is a heteroaryl selected from pyrazolyl, indolyl, pyrrolo[2,3-b]pyridinyl, pyrrolo[2,3-d]pyrimidinyl, pyrazolo[3,4-b]pyridinyl, pyrazolo[3,4-d]pyrimidinyl, 2,3-dihydro-1H-pyrrolo[2,3-b]pyridinyl, imidazo[4,5-b]pyridinyl, and purinyl, wherein said heteroaryl is substituted with Ra and Rb; and R1 and R2 are define herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases.
    Type: Application
    Filed: January 2, 2015
    Publication date: July 9, 2015
    Inventors: Joseph B. Santella, Sreekantha Ratna Kumar, John V. Duncia, Daniel S. Gardner, Venkatram Reddy Paidi, Satheesh Kesavan Nair, John Hynes, Hong Wu, Natesan Murugesan, Kandhasamy Sarkunam, Piramanayagam Arunachalam
  • Piperidinyl compound as a modulator of chemokine receptor activity
    Patent number: 8642622
    Abstract: The present application describes the compound of formula (I): or stereoisomers or pharmaceutically acceptable salts thereof. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and arthrosclerosis using the compound of the invention are disclosed.
    Type: Grant
    Filed: June 15, 2011
    Date of Patent: February 4, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Robert J. Cherney, John V. Duncia, Daniel S. Gardner, Joseph B. Santella, Zhongyu Wang
  • Piperidinyl derivative as a modulator of chemokine receptor activity
    Patent number: 8633226
    Abstract: The present application describes the compound of formula (I): or stereoisomers or pharmaceutically acceptable salts thereof. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and arthrosclerosis using the compound of the invention are disclosed.
    Type: Grant
    Filed: September 27, 2012
    Date of Patent: January 21, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventor: Joseph B. Santella
  • Piperidine derivatives as modulators of chemokine receptor activity
    Patent number: 8536198
    Abstract: The present application describes modulators of MIP-1 of formula (I): or stereoisomers or pharmaceutically acceptable salts thereof, wherein m, Q, T, W, Z, R1, R3, R4, R5, R5a and R5b, are as set forth above. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis using the modulators are disclosed.
    Type: Grant
    Filed: July 23, 2008
    Date of Patent: September 17, 2013
    Assignee: Bristol-Myers Squibb Company
    Inventors: Joseph B. Santella, John Hynes, Daniel S. Gardner
  • Piperidinyl derivatives as modulators of chemokine receptor activity
    Patent number: 8501782
    Abstract: The present application describes modulators of MIP-1? of formula (I) or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein m, Q, T, W, Z, R1, R3, R4, R5, R5a and R5b, are as defined herein. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis using the modulators of formula (I) are disclosed.
    Type: Grant
    Filed: July 23, 2008
    Date of Patent: August 6, 2013
    Assignee: Bristol-Myers Squibb Company
    Inventors: Daniel S. Gardner, John V. Duncia, John Hynes, T.G. Murali Dhar, Percy H. Carter, Joseph B. Santella
  • Prodrugs of a piperidinyl derivative as modulators of chemokine receptor activity
    Patent number: 8410139
    Abstract: The present application describes prodrugs of the compound of formula (I): or stereoisomers or pharmaceutically acceptable salts thereof. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis using the prodrug compounds of the invention are disclosed.
    Type: Grant
    Filed: October 4, 2010
    Date of Patent: April 2, 2013
    Assignee: Bristol-Myers Squibb Company
    Inventors: John Hynes, Percy H. Carter, Lyndon A. M. Cornelius, T.G. Murali Dhar, John V. Duncia, Satheesh Nair, Joseph B. Santella, Jayakumar S. Warrier, Hong Wu
  • Piperidinyl derivative as a modulator of chemokine receptor activity
    Patent number: 8299098
    Abstract: The present application describes the compound of formula (I): or stereoisomers or pharmaceutically acceptable salts thereof. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and arthrosclerosis using the compound of the invention are disclosed.
    Type: Grant
    Filed: June 24, 2009
    Date of Patent: October 30, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventor: Joseph B. Santella
  • PIPERIDINYL COMPOUND AS A MODULATOR OF CHEMOKINE RECEPTOR ACTIVITY
    Publication number: 20120149733
    Abstract: The present application describes the compound of formula (I): or stereoisomers or pharmaceutically acceptable salts thereof. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and arthrosclerosis using the compound of the invention are disclosed.
    Type: Application
    Filed: June 15, 2011
    Publication date: June 14, 2012
    Inventors: Robert J. Cherney, John V. Duncia, Daniel S. Gardner, Joseph B. Santella, Zhongyu Wang
  • PIPERIDINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
    Publication number: 20110245226
    Abstract: The present application describes substituted piperidinyl modulators of MIP-1? or CCR-1 or stereoisomers or pharmaceutically acceptable salts thereof. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and transplant rejection using said modulators are disclosed.
    Type: Application
    Filed: June 8, 2011
    Publication date: October 6, 2011
    Inventors: Percy H. Carter, Cullen L. Cavallaro, John V. Duncia, Daniel S. Gardner, John Hynes, Rui-Qin Liu, Joseph B. Santella, Dharmpal S. Dodd
  • Piperidinyl derivatives as modulators of chemokine receptor activity
    Patent number: 7985861
    Abstract: The present application describes substituted piperidinyl modulators of MIP-1? or CCR-1 or stereoisomers or pharmaceutically acceptable salts thereof. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and transplant rejection using said modulators are disclosed.
    Type: Grant
    Filed: July 20, 2009
    Date of Patent: July 26, 2011
    Assignee: Bristol-Myers Squibb Company
    Inventors: Percy H. Carter, Cullen L. Cavallaro, John V. Duncia, Daniel S. Gardner, John Hynes, Rui-Qin Liu, Joseph B. Santella, Dharmpal S. Dodd
  • PRODRUGS OF A PIPERIDINYL DERIVATIVE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
    Publication number: 20110082113
    Abstract: The present application describes prodrugs of the compound of formula (I): or stereoisomers or pharmaceutically acceptable salts thereof. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis using the prodrug compounds of the invention are disclosed.
    Type: Application
    Filed: October 4, 2010
    Publication date: April 7, 2011
    Inventors: John Hynes, Percy H. Carter, Lyndon A.M. Cornelius, T.G. Murali Dhar, John V. Duncia, Joseph B. Santella, Hong Wu, Satheesh Nair, Jayakumar S. Warrier
  • PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
    Publication number: 20100222366
    Abstract: The present application describes modulators of MIP-1 of formula (I): or stereoisomers or pharmaceutically acceptable salts thereof, wherein m, Q, T, W, Z, R1, R3, R4, R5, R5a and R5b, are as set forth above. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis using the modulators are disclosed.
    Type: Application
    Filed: July 23, 2008
    Publication date: September 2, 2010
    Inventors: Joseph B. Santella, John Hynes, Daniel S. Gardner
  • PIPERIDINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
    Publication number: 20100204274
    Abstract: The present application describes modulators of MIP-1? of formula (I) or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein m, Q, T, W, Z, R1, R3, R4, R5, R5a and R5b, are as defined herein. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis using the modulators of formula (I) are disclosed.
    Type: Application
    Filed: July 23, 2008
    Publication date: August 12, 2010
    Inventors: Daniel S. Gardner, John V. Duncia, John Hynes, T.G. Murali Dhar, Percy H. Carter, Joseph B. Santella
  • PIPERIDINYL DERIVATIVE AS A MODULATOR OF CHEMOKINE RECEPTOR ACTIVITY
    Publication number: 20090326010
    Abstract: The present application describes the compound of formula (I): or stereoisomers or pharmaceutically acceptable salts thereof. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and arthrosclerosis using the compound of the invention are disclosed.
    Type: Application
    Filed: June 24, 2009
    Publication date: December 31, 2009
    Inventor: Joseph B. Santella
  • PIPERIDINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
    Publication number: 20090298833
    Abstract: The present application describes substituted piperidinyl modulators of MIP-1? or CCR-1 or stereoisomers or pharmaceutically acceptable salts thereof. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and transplant rejection using said modulators are disclosed.
    Type: Application
    Filed: July 20, 2009
    Publication date: December 3, 2009
    Inventors: Percy H. Carter, Cullen L. Cavallaro, John V. Duncia, Daniel S. Gardner, John Hynes, Rui-Qin Liu, Joseph B. Santella, Dharmpal S. Dodd
  • Piperidinyl derivatives as modulators of chemokine receptor activity
    Patent number: 7601844
    Abstract: The present application describes substituted piperidinyl modulators of MIP-1? or CCR-1 or stereoisomers or pharmaceutically acceptable salts thereof. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and transplant rejection using said modulators are disclosed.
    Type: Grant
    Filed: January 23, 2007
    Date of Patent: October 13, 2009
    Assignee: Bristol-Myers Squibb Company
    Inventors: Percy H. Carter, Cullen L. Cavallaro, John V. Duncia, Daniel S. Gardner, John Hynes, Rui-Qin Liu, Joseph B. Santella, Dharmpal S. Dodd
  • Bicyclic and tricyclic amines as modulators of chemokine receptor activity
    Patent number: 7550500
    Abstract: The present application describes modulators of CCR3 of formula (I): A—E—NR1—G??(I) or pharmaceutically acceptable salt forms thereof, useful for the prevention of inflammatory diseases such as asthma and other allergic diseases.
    Type: Grant
    Filed: September 13, 2005
    Date of Patent: June 23, 2009
    Assignee: Bristol-Myers Squibb Company
    Inventors: John V Duncia, Joseph B Santella, III, Daniel S Gardner, Dean A Wacker
  • Cyclic derivatives as modulators of chemokine receptor activity
    Patent number: 7338947
    Abstract: The present application describes modulators of MCP-1 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of rheumatoid arthritis, multiple sclerosis, atherosclerosis and asthma, processes for preparing and intermediates thereof.
    Type: Grant
    Filed: October 10, 2006
    Date of Patent: March 4, 2008
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Robert J. Cherney, Percy H. Carter, John V. Duncia, Daniel S. Gardner, Joseph B. Santella